Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H28N2O4 |
Molecular Weight | 336.4259 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
InChI
InChIKey=GOEMGAFJFRBGGG-UHFFFAOYSA-N
InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
Molecular Formula | C18H28N2O4 |
Molecular Weight | 336.4259 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. Acebutolol is marketed under the trade names Sectral, Prent. Acebutolol is indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Acebutolol is also indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. Acebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2859774
Curator's Comment: Acebutolol is relatively hydrophilic and does not readily cross the blood-brain barrier, a fact that may be clinically significant in reducing the frequency and severity of central nervous system adverse effects.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
741.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SECTRAL Approved UseINDICATIONS & USAGE HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. Launch Date1984 |
|||
Primary | SECTRAL Approved UseINDICATIONS & USAGE HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. Launch Date1984 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
92 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6884417/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACEBUTOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4492 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6884417/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACEBUTOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 h |
unknown, oral |
ACEBUTOLOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
74% |
unknown, oral |
ACEBUTOLOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
Other AEs: Breathing shallow, Nausea... Other AEs: Breathing shallow Sources: Nausea Pulse thready Tachycardia Bradycardia Asystole Death (grade 5) Blood pressure low |
9.2 g 1 times / day single, oral Overdose Dose: 9.2 g, 1 times / day Route: oral Route: single Dose: 9.2 g, 1 times / day Sources: |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: M Population Size: 1 Sources: |
Other AEs: Blood pressure low, Heart rate low... Other AEs: Blood pressure low Sources: Heart rate low Necrosis bowel Muscle tone flaccid |
0.8 g 2 times / day multiple, oral Highest studied dose Dose: 0.8 g, 2 times / day Route: oral Route: multiple Dose: 0.8 g, 2 times / day Sources: |
unhealthy, 31-63 n = 11 Health Status: unhealthy Condition: hypertension Age Group: 31-63 Sex: M+F Population Size: 11 Sources: |
Disc. AE: Antinuclear antibody... AEs leading to discontinuation/dose reduction: Antinuclear antibody (3 patients) Sources: |
4 g 1 times / day single, oral Overdose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 43 n = 1 Health Status: healthy Age Group: 43 Sex: F Population Size: 1 Sources: |
Other AEs: Blood pressure low, Ventricular tachycardia... Other AEs: Blood pressure low Sources: Ventricular tachycardia Death (grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Asystole | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Blood pressure low | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Bradycardia | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Breathing shallow | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Nausea | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Pulse thready | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Tachycardia | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
|
Death | grade 5 | 6 g 1 times / day single, oral Overdose Dose: 6 g, 1 times / day Route: oral Route: single Dose: 6 g, 1 times / day Sources: |
healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: |
Blood pressure low | 9.2 g 1 times / day single, oral Overdose Dose: 9.2 g, 1 times / day Route: oral Route: single Dose: 9.2 g, 1 times / day Sources: |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: M Population Size: 1 Sources: |
|
Heart rate low | 9.2 g 1 times / day single, oral Overdose Dose: 9.2 g, 1 times / day Route: oral Route: single Dose: 9.2 g, 1 times / day Sources: |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: M Population Size: 1 Sources: |
|
Muscle tone flaccid | 9.2 g 1 times / day single, oral Overdose Dose: 9.2 g, 1 times / day Route: oral Route: single Dose: 9.2 g, 1 times / day Sources: |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: M Population Size: 1 Sources: |
|
Necrosis bowel | 9.2 g 1 times / day single, oral Overdose Dose: 9.2 g, 1 times / day Route: oral Route: single Dose: 9.2 g, 1 times / day Sources: |
healthy, 24 n = 1 Health Status: healthy Age Group: 24 Sex: M Population Size: 1 Sources: |
|
Antinuclear antibody | 3 patients Disc. AE |
0.8 g 2 times / day multiple, oral Highest studied dose Dose: 0.8 g, 2 times / day Route: oral Route: multiple Dose: 0.8 g, 2 times / day Sources: |
unhealthy, 31-63 n = 11 Health Status: unhealthy Condition: hypertension Age Group: 31-63 Sex: M+F Population Size: 11 Sources: |
Blood pressure low | 4 g 1 times / day single, oral Overdose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 43 n = 1 Health Status: healthy Age Group: 43 Sex: F Population Size: 1 Sources: |
|
Ventricular tachycardia | 4 g 1 times / day single, oral Overdose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 43 n = 1 Health Status: healthy Age Group: 43 Sex: F Population Size: 1 Sources: |
|
Death | grade 5 | 4 g 1 times / day single, oral Overdose Dose: 4 g, 1 times / day Route: oral Route: single Dose: 4 g, 1 times / day Sources: |
healthy, 43 n = 1 Health Status: healthy Age Group: 43 Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Pharmacology of acebutolol in animals]. | 1975 Dec 31 |
|
Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. | 1992 Jul |
|
Pharmacokinetics of acebutolol and its main metabolite, diacetolol after oral administration of acebutolol in rabbits with carbon tetrachloride-induced hepatic failure. | 2002 Aug |
|
Beta-adrenergic blockade during severe ischemia. | 2002 Dec |
|
Electrocardiographic changes associated with beta-blocker toxicity. | 2002 Dec |
|
[Acute poisoning with nifedipine and acebutol: two cases]. | 2003 |
|
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. | 2003 Aug |
|
Changes in serum lipids and antioxidant status in west Algerian patients with essential hypertension treated with acebutolol compared to healthy subjects. | 2003 Aug |
|
Sleep-deprived mice show altered cytokine production manifest by perturbations in serum IL-1ra, TNFa, and IL-6 levels. | 2003 Dec |
|
[Toxicologic analysis of some adrenergic-beta blockers in the diagnosis of intoxications]. | 2003 Oct-Dec |
|
Determination of stability constants of the inclusion complexes of beta-blockers in heptakis (2,3-dimethyl-6-sulfato)-beta-cyclodextrin. | 2004 Dec |
|
Isotachophoresis of beta-blockers in a capillary and on a poly(methyl methacrylate) chip. | 2004 Jun |
|
Spectrophotometric determination of some beta-blockers in dosage forms based on complex formation with Cu(II) and Co(II). | 2004 Jun |
|
Medication error caused by confusing drug blisters. | 2004 Jun 26 |
|
[Antihypertensive therapy with left cardiac insufficiency]. | 2005 Dec |
|
Effects of grapefruit juice on the pharmacokinetics of acebutolol. | 2005 Dec |
|
Assay of acebutolol in pharmaceuticals by analytical capillary isotachophoresis. | 2005 Jul 15 |
|
Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. | 2005 Oct |
|
Acebutolol-induced subacute cutaneous lupus erythematosus. | 2005 Sep-Oct |
|
Stability of atenolol, acebutolol and propranolol in acidic environment depending on its diversified polarity. | 2006 |
|
Spectrophotometric and spectrofluorimetric methods for analysis of tramadol, acebutolol and dothiepin in pharmaceutical preparations. | 2006 Dec |
|
UPLC/MS for the identification of beta-blockers. | 2006 Feb 24 |
|
Spectrofluorimetric determination of drugs containing active methylene group using N1-methyl nicotinamide chloride as a fluorigenic agent. | 2006 Jul |
|
Spectrophotometric and spectrofluorimetric methods for analysis of acyclovir and acebutolol hydrochloride. | 2006 Nov |
|
Analysis of neutral and basic pharmaceuticals in sewage treatment plants and in recipient rivers using solid phase extraction and liquid chromatography-tandem mass spectrometry detection. | 2006 Nov 17 |
|
Abstracts of papers presented at the 2007 pittsburgh conference. | 2007 |
|
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. | 2007 |
|
[Interrelationship between changes of rate and variability of cardiac rhythm under influence of beta-adrenoblockers]. | 2007 |
|
Clinical review: aggressive management and extracorporeal support for drug-induced cardiotoxicity. | 2007 |
|
A population-based analysis of the class effect of beta-blockers after myocardial infarction. | 2007 Feb |
|
Spectrophotometric and spectrofluorimetric methods for analysis of acyclovir and acebutolol hydrochloride. | 2007 Jan |
|
Evaluation of chromatographic descriptors for the prediction of gastro-intestinal absorption of drugs. | 2007 Jan 5 |
|
Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. | 2007 Jul-Aug |
|
Amoxicillin-Induced Eosinophilic Pneumonia with Granulomatous Reaction: Discrepancy between Drug-Induced Lymphocyte Stimulation Test Findings and the Provocation Drug Test. | 2007 Jun 15 |
|
Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. | 2007 Mar |
|
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. | 2007 Oct 16 |
|
Evaluation of the impact on entomocoenosis of active agents allowed in organic olive farming against Bactrocera oleae (Gmelin, 1790). | 2007 Sep-Oct |
|
Simultaneous determination of beta-blockers in human plasma using liquid chromatography-tandem mass spectrometry. | 2008 Jul |
|
Ozonation of reverse osmosis concentrate: kinetics and efficiency of beta blocker oxidation. | 2008 Jun |
|
Stability of chosen beta-adrenolytic drugs of different polarity in basic environment. | 2008 Mar-Apr |
|
Determination of selected beta-receptor antagonists in biological samples by solid-phase extraction with cholesterolic phase and LC/MS. | 2009 Jan |
|
Using supported liquid extraction together with cellobiohydrolase chiral stationary phases-based liquid chromatography with tandem mass spectrometry for enantioselective determination of acebutolol and its active metabolite diacetolol in spiked human plasma. | 2009 Jan 15 |
|
[Beta blockers in migraine prophylaxis]. | 2009 Oct |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Medicinal chemistry of drugs used in diabetic cardiomyopathy. | 2010 |
|
Management of infantile subglottic hemangioma: acebutolol or propranolol? | 2010 Aug |
|
Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. | 2010 Feb 24 |
|
Principal component analysis of HPLC retention data and molecular modeling structural parameters of cardiovascular system drugs in view of their pharmacological activity. | 2010 Jul 9 |
|
Potential for biodegradation and sorption of acetaminophen, caffeine, propranolol and acebutolol in lab-scale aqueous environments. | 2010 Nov 15 |
|
Occurrence and removal of estrogens and beta blockers by various processes in wastewater treatment plants. | 2010 Sep 1 |
Sample Use Guides
Hypertension
The initial dosage of acebutolol in uncomplicated mild-to-moderate hypertension is 400 mg. This can be given as a single daily dose, but in occasional patients twice daily dosing may be required for adequate 24-hour blood-pressure control. An optimal response is usually achieved with dosages of 400 to 800 mg per day, although some patients have been maintained on as little as 200 mg per day. Patients with more severe hypertension or who have demonstrated inadequate control may respond to a total of 1200 mg daily (administered b.i.d.), or to the addition of a second antihypertensive agent. Beta-1 selectivity diminishes as dosage is increased.
Ventricular Arrhythmia
The usual initial dose of acebutolol is 400 mg daily given as 200 mg b.i.d. Dosage should be increased gradually until an optimal clinical response is obtained, generally at 600 to 1200 mg per day. If treatment is to be discontinued, the dosage should be reduced gradually over a period of about two weeks.
Use in Older Patients
Older patients have an approximately 2-fold increase in bioavailability and may require lower maintenance doses. Doses above 800 mg/day should be avoided in the elderly.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6115715
Two adrenergic receptor antagonists, acebutolol and propranolol, were observed to depress rabbit heart contractile force and adrenaline-stimulated adenylate cyclase activity at 1 X 10-(5) to 1 X 10-(3) M and 1 X 10-(6) to 1 X 10-(3) M concentrations, respectively. Acebutolol depressed sarcoplasmic reticular and mitochondrial calcium uptake at 5 X 10-(3) to 10-(2) M concentrations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:40:21 GMT 2023
by
admin
on
Fri Dec 15 17:40:21 GMT 2023
|
Record UNII |
67P356D8GH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07AB04
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
NDF-RT |
N0000175556
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
NDF-RT |
N0000000161
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
WHO-VATC |
QC07AB04
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
LIVERTOX |
NBK548853
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
WHO-ATC |
C07BB04
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3295
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
D000070
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
C61525
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
1978
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
67P356D8GH
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
253-539-0
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
DB01193
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
100000092351
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
149
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB07371MIG
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
m1290
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
Acebutolol
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
67P356D8GH
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
2379
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
DTXSID2048539
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
37517-30-9
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL642
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
40
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
ACEBUTOLOL
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY | |||
|
7107
Created by
admin on Fri Dec 15 17:40:21 GMT 2023 , Edited by admin on Fri Dec 15 17:40:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
ENANTIOMER -> RACEMATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||